These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 32477116)

  • 1. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.
    Xu Y; Guo W; Zhang C; Chen F; Tan HY; Li S; Wang N; Feng Y
    Front Pharmacol; 2020; 11():601. PubMed ID: 32477116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S; Younossi ZM
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steatosis and NASH in type 2 diabetes.
    Hu M; Phan F; Bourron O; Ferré P; Foufelle F
    Biochimie; 2017 Dec; 143():37-41. PubMed ID: 29097281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease.
    Smith BW; Adams LA
    Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review.
    Kaur S; Sojitra V; Zahra A; Hutchinson J; Folawemi O; Bittla P; Ramphall S
    Cureus; 2023 Sep; 15(9):e45789. PubMed ID: 37745748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.
    Ore A; Akinloye OA
    Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease.
    Liu C; Liao JZ; Li PY
    World J Gastroenterol; 2017 Mar; 23(11):1964-1973. PubMed ID: 28373762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation.
    Farzanegi P; Dana A; Ebrahimpoor Z; Asadi M; Azarbayjani MA
    Eur J Sport Sci; 2019 Aug; 19(7):994-1003. PubMed ID: 30732555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.
    Gehrke N; Wörns MA; Huber Y; Hess M; Straub BK; Hövelmeyer N; Waisman A; Kim YO; Schuppan D; Galle PR; Schattenberg JM
    J Hepatol; 2016 Dec; 65(6):1188-1197. PubMed ID: 27405060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Therapeutic Implication of Herbal Medicine in Mitochondria-Mediated Oxidative Stress-Related Liver Diseases.
    Park MN; Rahman MA; Rahman MH; Kim JW; Choi M; Kim JW; Choi J; Moon M; Ahmed KR; Kim B
    Antioxidants (Basel); 2022 Oct; 11(10):. PubMed ID: 36290765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations.
    Adinolfi LE; Rinaldi L; Guerrera B; Restivo L; Marrone A; Giordano M; Zampino R
    Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27231906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease.
    Jiang M; Li C; Liu Q; Wang A; Lei M
    Front Endocrinol (Lausanne); 2019; 10():665. PubMed ID: 31616384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
    Tacke F; Weiskirchen R
    Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
    Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
    Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.
    Dallio M; Sangineto M; Romeo M; Villani R; Romano AD; Loguercio C; Serviddio G; Federico A
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.